Ascendis Pharma A/S (ASND) to Release Earnings on Thursday

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) is expected to announce its Q1 2025 earnings results before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of ($1.56) per share and revenue of $98.56 million for the quarter.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($1.32) by $0.64. On average, analysts expect Ascendis Pharma A/S to post $-4 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ascendis Pharma A/S Trading Down 0.6 %

ASND opened at $158.14 on Thursday. The company's 50 day moving average is $153.31 and its 200 day moving average is $138.53. The company has a market cap of $9.64 billion, a price-to-earnings ratio of -22.27 and a beta of 0.54. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $169.37.

Wall Street Analyst Weigh In

ASND has been the topic of several analyst reports. Evercore ISI lifted their price target on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an "outperform" rating in a report on Tuesday, February 18th. JPMorgan Chase & Co. increased their target price on Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 18th. The Goldman Sachs Group upped their target price on Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. Royal Bank of Canada initiated coverage on shares of Ascendis Pharma A/S in a research report on Wednesday, April 16th. They set an "outperform" rating and a $205.00 target price on the stock. Finally, UBS Group started coverage on Ascendis Pharma A/S in a report on Tuesday, January 7th. They issued a "buy" rating and a $196.00 price target for the company. Two analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $204.67.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.